Insights into the trimeric HIV-1 envelope glycoprotein structure

Trends in Biochemical Sciences

Volumn 40, Issue 2, 2015, Pages 101-107

  Ward, Andrew B ^a   Wilson, Ian A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Broadly neutralizing antibodies; Envelope glycoprotein trimer; HIV 1; Structure

Indexed keywords

EPITOPE; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; NEUTRALIZING ANTIBODY; VIRUS FUSION PROTEIN;

ANTIBODY DETECTION; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CRYSTALLIZATION; CRYSTALLOGRAPHY; ELECTRON MICROSCOPY; ELECTRON TOMOGRAPHY; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; MOLECULAR DYNAMICS; NEXT GENERATION SEQUENCING; NONHUMAN; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ANALYSIS; VIRUS NEUTRALIZATION; CD4+ T LYMPHOCYTE; CHEMISTRY; CONFORMATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; PATHOGENICITY; PATHOLOGY; PROTEIN MULTIMERIZATION; VIROLOGY; X RAY CRYSTALLOGRAPHY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODIES, NEUTRALIZING; CD4-POSITIVE T-LYMPHOCYTES; CRYSTALLOGRAPHY, X-RAY; GENE PRODUCTS, ENV; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR CONFORMATION; PROTEIN MULTIMERIZATION; VIRAL FUSION PROTEINS;

EID: 84921606536     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2014.12.006     Document Type: Review

References (60)

1. Wyatt R., et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998, 393:705-711.
2. Huang C.C., et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310:1025-1028.
3. Pancera M., et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:1166-1171.
4. Zhou T., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445:732-737.
5. Diskin R., et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 2011, 334:1289-1293.
6. Garces F., et al. Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 2014, 159:69-79.
7. Georgiev I.S., et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 2013, 340:751-756.
8. Klein F., et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013, 153:126-138.
9. Kong L., et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 2013, 20:796-803.
10. Liao H.X., et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013, 496:469-476.
11. Pejchal R., et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011, 334:1097-1103.
12. Scharf L., et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 2014, 7:785-795.
13. Wu X., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602.
14. Zhou T., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329:811-817.
15. Zhou T., et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 2013, 39:245-258.
16. Kwon Y.D., et al. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:5663-5668.
17. Kwong P.D., et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
18. Walker L.M., Burton D.R. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 2010, 22:358-366.
19. Julien J.P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1477-1483.
20. Lyumkis D., et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1484-1490.
21. Pancera M., et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 2014, 514:455-461.
22. Zanetti G., et al. Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog. 2006, 2:e83.
23. Zhu P., et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006, 441:847-852.
24. Zhu P., et al. Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs. PLoS Pathog. 2008, 4:e1000203.
25. Harris A., et al. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:11440-11445.
26. Liu J., et al. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455:109-113.
27. Pancera M., et al. Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis. J. Virol. 2005, 79:9954-9969.
28. Yang X., et al. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 2002, 76:4634-4642.
29. Ringe R.P., et al. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:18256-18261.
30. Tran K., et al. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:E738-E747.
31. Binley J.M., et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J. Virol. 2000, 74:627-643.
32. Sanders R.W., et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 2002, 76:8875-8889.
33. Sanders R.W., et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013, 9:e1003618.
34. Khayat R., et al. Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J. Virol. 2013, 87:9865-9872.
35. Klasse P.J., et al. Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J. Virol. 2013, 87:9873-9885.
36. Blattner C., et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 2014, 40:669-680.
37. Falkowska E., et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 2014, 40:657-668.
38. Bartesaghi A., et al. Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat. Struct. Mol. Biol. 2013, 20:1352-1357.
39. Weissenhorn W., et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387:426-430.
40. Jardine J., et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013, 340:711-716.
41. McGuire A.T., et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 2013, 210:655-663.
42. McCaffrey R.A., et al. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J. Virol. 2004, 78:3279-3295.
43. Murin C.D., et al. Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy. J. Virol. 2014, 88:10177-10188.
44. Sok D., et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci. Transl. Med. 2014, 6:236ra263.
45. Bonomelli C., et al. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 2011, 6:e23521.
46. Julien J.P., et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:4351-4356.
47. McLellan J.S., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-343.
48. Pancera M., et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat. Struct. Mol. Biol. 2013, 20:804-813.
49. Doria-Rose N.A., et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014, 509:55-62.
50. Wibmer C.K., et al. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 2013, 9:e1003738.
51. Harvey D.J., et al. MALDI-MS/MS with traveling wave ion mobility for the structural analysis of N-linked glycans. J. Am. Soc. Mass Spectrom. 2012, 23:1955-1966.
52. Harvey D.J., et al. Travelling wave ion mobility and negative ion fragmentation for the structural determination of N-linked glycans. Electrophoresis 2013, 34:2368-2378.
53. Harvey D.J., et al. Ion mobility mass spectrometry for extracting spectra of N-glycans directly from incubation mixtures following glycan release: application to glycans from engineered glycoforms of intact, folded HIV gp120. J. Am. Soc. Mass Spectrom. 2011, 22:568-581.
54. Kassa A., et al. Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain. J. Virol. 2009, 83:8364-8378.
55. Tran E.E., et al. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog. 2012, 8:e1002797.
56. Li Y., et al. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins. J. Virol. 2012, 86:11231-11241.
57. Huang J., et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 2014, 515:138-142.
58. Davenport T.M., et al. Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120. J. Virol. 2013, 87:10855-10873.
59. Guttman M., et al. CD4-induced activation in a soluble HIV-1 Env trimer. Structure 2014, 22:974-984.
60. Munro J.B., et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 2014, 34:759-763.